probenecid has been researched along with Carcinoma, Transitional Cell in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitamura, T | 1 |
| Homma, Y | 1 |
| Nishimura, Y | 1 |
1 other study available for probenecid and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
[A case of familial renal hypouricemia associated with bladder cancer].
Topics: Aged; Benzbromarone; Carcinoma, Transitional Cell; Humans; Male; Probenecid; Pyrazinamide; Renal Tub | 1984 |